--- title: "14:32 ETGovernment Expands GLP-1 Access -- Menu-Order-AI Powers Everyday Decision Support" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/277669848.md" description: "The Centers for Medicare & Medicaid Services (CMS) has launched the BALANCE Model to expand access to GLP-1 medications under Medicare and Medicaid. This initiative aims to improve consumer behavior regarding dietary choices by integrating clinical guidance into everyday dining through the Menu-Order-AI platform. The app helps users find high-protein, GLP-1 friendly options at restaurants, reflecting a growing demand for tools that support metabolic health. As GLP-1 adoption increases, the need for real-time decision-making support in healthcare and hospitality is expected to rise." datetime: "2026-03-03T19:33:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277669848.md) - [en](https://longbridge.com/en/news/277669848.md) - [zh-HK](https://longbridge.com/zh-HK/news/277669848.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277669848.md) | [English](https://longbridge.com/en/news/277669848.md) # 14:32 ETGovernment Expands GLP-1 Access -- Menu-Order-AI Powers Everyday Decision Support _Federal Policy Signals Accelerating GLP-1 Adoption — Menu-Order-AI Translates Clinical Access into Everyday Dining Decisions_ , /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) has announced the BALANCE Model, a voluntary initiative designed to expand access to GLP-1 medications under Medicare and Medicaid through negotiated pricing and structured coverage. GLP-1 treatment is now embedded in federal healthcare policy. As access expands, consumer behavior shifts. Clinical guidance for GLP-1 patients emphasizes protein prioritization, portion control, and structured nutrition support to improve long-term outcomes. Yet millions of Americans still face a daily challenge: how to apply that guidance in real-world restaurant settings. **Menu-Order-AI** was built to solve that gap. The platform instantly analyzes any restaurant menu and highlights: • High-protein • GLP-1 friendly options — helping users translate metabolic goals into practical dining decisions from one restaurant choice or scan of a menu. The company recently surpassed **50,000 downloads** and is trusted by over **20,000 users across 25+ countries**, reflecting accelerating global demand for protein-prioritized, GLP-1 aligned dining tools. Global adoption continues to scale following the company's integration of Google Places technology. The integration strengthens Menu-Order-AI's global infrastructure, ensuring precise restaurant identification and scalable international coverage — capabilities legacy directory solutions were unable to consistently deliver at scale. _"The expansion of GLP-1 access at the federal level confirms this is not a trend — it's a structural shift in how Americans approach food and metabolic health. Prescriptions don't make choices at restaurants — people do. Menu-Order-AI turns clinical access into real-world, high-protein, GLP-1 friendly decisions from one restaurant choice or scan of a menu,"_ says Melissa Butler, Founder of Menu-Order-AI. As national GLP-1 adoption accelerates, the demand for real-time behavioral support tools is expected to grow across healthcare, hospitality, and technology sectors. GLP-1 access is scaling nationally. The infrastructure supporting everyday decision-making must scale with it. **About Menu-Order-AI** Menu-Order-AI is the GLP-1 dining companion, instantly analyzing restaurant menus to surface high-protein, GLP-1 friendly options that align with metabolic health goals. Website https://www.menuorderai.com/ App Store https://apps.apple.com/us/app/menu-order-ai-find-glp1-meals/id6753690910 Google play store https://play.google.com/store/apps/details?id=co.menu.order&pcampaignid=web\_share **Melissa Butler** Founder Menu-Order AI \[email protected\] This release was issued through WebWire®. For more information, visit http://www.webwire.com. SOURCE MENU - ORDER AI ### 相關股票 - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [Defiance Daily Target 2X Long LLY ETF (LLYX.US)](https://longbridge.com/zh-HK/quote/LLYX.US.md) - [Direxion Daily LLY Bull 2X Shares (ELIL.US)](https://longbridge.com/zh-HK/quote/ELIL.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-HK/quote/NVO.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-HK/quote/IHI.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [Defiance Daily Target 2X Long NVO ETF (NVOX.US)](https://longbridge.com/zh-HK/quote/NVOX.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-HK/quote/XHE.US.md) ## 相關資訊與研究 - [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-HK/news/278565253.md) - [](https://longbridge.com/zh-HK/news/278768331.md) - [Eli Lily to Spend USD3 Billion to Boost China Production of Next-Gen GLP-1 Weight-Loss Drug Over Next Decade](https://longbridge.com/zh-HK/news/278831711.md) - [Eli Lilly Targets $3 Billion Investments to Expand Production Capacity in China](https://longbridge.com/zh-HK/news/278821486.md) - [](https://longbridge.com/zh-HK/news/278902994.md)